Prostate carcinoma: measures to improve therapeutic response and prevent complications.
Between 1965 and 1973, 80 patients with prostatic carcinoma were treated with definitive supervoltage irradiation; 35 patients received adjuvant estrogens. A favorable tumor response was uniformly observed in patients with less advanced tumors who received a minimum of 6,000 rads tumor dose and adjuvant estrogens. Radiation complications were frequent and severe in patients with locally advanced tumors who had antecedent lower urinary tract surgery and received a minimum of 7,000 rads tumor dose. Complications were less frequent in patients who received adjuvant estrogens, and complications were uncommon and mild in patients who received less than 7,000 rads.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D000328:Adult; D000368:Aged; D003037:Cobalt Radioisotopes; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011867:Radioisotope Teletherapy; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D012002:Rectal Diseases / Q000517:prevention & control*; D014570:Urologic Diseases / Q000517:prevention & control*
D003037:Cobalt Radioisotopes; D004967:Estrogens